The human L-threonine 3-dehydrogenase gene is an expressed pseudogene
© Edgar. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. 2002
Received: 29 July 2002
Accepted: 2 October 2002
Published: 2 October 2002
L-threonine is an indispensable amino acid. One of the major L-threonine degradation pathways is the conversion of L-threonine via 2-amino-3-ketobutyrate to glycine. L-threonine dehydrogenase (EC 188.8.131.52) is the first enzyme in the pathway and catalyses the reaction: L-threonine + NAD+ = 2-amino-3-ketobutyrate + NADH. The murine and porcine L-threonine dehydrogenase genes (TDH) have been identified previously, but the human gene has not been identified.
The human TDH gene is located at 8p23-22 and has 8 exons spanning 10 kb that would have been expected to encode a 369 residue ORF. However, 2 cDNA TDH transcripts encode truncated proteins of 157 and 230 residues. These truncated proteins are the result of 3 mutations within the gene. There is a SNP, A to G, present in the genomic DNA sequence of some individuals which results in the loss of the acceptor splice site preceding exon 4. The acceptor splice site preceding exon 6 was lost in all 23 individuals genotyped and there is an in-frame stop codon in exon 6 (CGA to TGA) resulting in arginine-214 being replaced by a stop codon. These truncated proteins would be non-functional since they have lost part of the NAD+ binding motif and the COOH terminal domain that is thought to be involved in binding L-threonine. TDH mRNA was present in all tissues examined.
The human L-threonine 3-dehydrogenase gene is an expressed pseudogene having lost the splice acceptor site preceding exon 6 and codon arginine-214 (CGA) is mutated to a stop codon (TGA).
Liver failure is a cause of considerable mortality; therefore bioartificial livers may offer significant therapeutic benefit. Porcine-derived hepatocytes are being used in clinical studies of bioartificial livers [1, 2]. There may, however, be significant differences in the activities of liver enzymes between species . These differences are also important considerations when the pharmaceutical industry conducts new drug metabolism and pharmacokinetic studies on key mammal species .
The liver plays a critical role in regulating the circulating concentrations of amino acids. The regulation of amino acid supply to bioartificial organs and maintaining the activity of the amino acid-metabolising enzymes will be important in their development. Active maintenance of the optimal amino acid concentrations will offer the possibility of prolonging the differentiated function of hepatocytes in bioartificial livers .
L-threonine is one of three indispensable amino acids since mammals do not possess the necessary enzymes for the transamination of threonine . However, the transient apoenzyme form of L-threonine dehydratase bound to pyridoxamine 5'-phosphate dehydratase can carry out a half-transamination of L-threonine . Once L-threonine is oxidised through various catabolic pathways it is lost for the purposes of protein synthesis. Therefore, it is important for determining levels of human nutrition that factors regulating threonine oxidation are identified. The international recommended intake of L-threonine for adults is 7 mg.kg-1.d-1. However, this has recently been challenged as being too low and a recommendation of 15 mg.kg-1.d-1 has been suggested .
There are two major L-threonine degradation pathways. L-threonine is either catabolised by L-threonine 3-dehydrogenase to 2-amino-3-ketobutyrate or by L-serine/threonine dehydratase (EC 184.108.40.206) to NH4 + and 2-ketobutyrate. In both eukaryotic and prokaryotic cells, the conversion of L-threonine via 2-amino-3-ketobutyrate to glycine takes place in a two-step process [10, 11]. L-threonine dehydrogenase catalyses the reaction: L-threonine + NAD+ = 2-amino-3-ketobutyrate + NADH. The subsequent reaction between 2-amino-3-ketobutyrate and coenzyme A to form glycine and acetyl-CoA is catalysed by 2-amino-3-ketobutyrate coenzyme A ligase (EC 220.127.116.11 also called glycine acetyltransferase; gene names KBL and GCAT). L-threonine dehydrogenase and 2-amino-3-ketobutyrate coenzyme A ligase are associated physically on the inner membrane-matrix of mitochondria where the two enzymes form a complex with a stoichiometry of one threonine dehydrogenase tetramer to two 2-amino-3-ketobutyrate coenzyme A ligase dimers [12–14].
In mammals, the removal of the 1-carbon of threonine is thought to occur through threonine dehydrogenase, this carbon being incorporated into glycine and released as CO2 by the mitochondrial glycine cleavage system. In normally-fed pigs and rats 80 to 87% of L-threonine catabolism occurs via threonine dehydrogenase [15, 16] and in isolated rat and cat hepatocytes 35% to 50% of threonine oxidation occurs through this pathway [17, 18]. Zhao et al. measured threonine oxidation in adult humans by the production of labelled CO2 from L-[1-13C]threonine and concluded that the conversion of threonine to glycine through the threonine dehydrogenase pathway was not important if it exists at all . However, the dehydrogenase pathway is thought to account for 44% of total threonine oxidation in infants . More recently, the same group used a more sensitive method to measure the production of labelled glycine and CO2 in adults and suggested that there was some threonine catabolism via the threonine dehydrogenase pathway, but it accounted for only 7–11% of total . This suggested that the L-serine/threonine dehydratase pathway is the dominant route in the catabolism of threonine in humans.
Recently, the sequences of the murine and porcine TDH cDNAs have been reported . The amino-terminal regions of these proteins have characteristics of a mitochondrial targeting sequence and are related to the UDP-galactose 4-epimerases, with both enzyme families having an amino-terminal NAD+ binding domain. The sequence of the human KBL transcript, the second enzyme in the pathway, has also been described  and this study aimed to identify the human TDH gene.
Human TDH gene
Human TDH protein
Human TDH predicted secondary structure
Mutations in the human TDH gene
However, there are 3 mutations that disrupt the gene transcription and translation on the sequence of genomic clone RP11-110L10 (Fig. 2). There is a loss of the acceptor splice sites in exon 4 and 6 and an in-frame stop codon in exon 6 (from the expected CGA to TGA) resulting in arginine-214 being replaced by a stop codon. Together, these mutations suggested that the human TDH gene is a pseudogene.
Genotyping of individuals by restriction enzyme digests and DNA sequencing
Copy DNA sequences of the human TDH gene
Expression of the TDH pseudogene in human tissue and cell types
A search of the human genomic sequences for the TDH gene identified only one candidate location on chromosome 8p23-22. This is the expected site of the human TDH gene since there are a number of genes that neighbour the TDH genes in the genomes of human, mouse and puffer fish that are found in common in this locus. They are the myotubularin related protein 8, the B-lymphoid tyrosine kinase and the hypothetical protein C8orf13. There are differences in the gene order and orientation in the human and puffer fish TDH loci indicating that there have been re-arrangements in this locus since the divergence of the human and puffer fish lineages .
The human TDH gene contains 3 mutations that disrupt the gene transcription and translation. There is a loss of the acceptor splice sites preceding exons 4 and 6 and an in-frame stop codon in exon 6. A database search of expressed human sequences identified other TDH cDNAs and ESTs similar to the 2 cDNA sequences described. The sequence of the human cerebellum full-length cDNA clone FLJ25033 (AK057762, NEDO human cDNA sequencing project University of Tokyo, Japan) has 2 5'UTR exons, the first of which corresponds to exon -1 on the mouse genomic DNA sequence . This clone skips both exons 4 and 6, and includes the polyadenylation site. The ORF would encode a truncated 180 residue protein. Three very similar human ESTs (AI005002, AI243637 and AI809781) have exon 4 skipped and use the cryptic acceptor splice site in exon 6 that was found in clone 2 and possesses the in-frame stop codon.
The human TDH gene is a pseudogene because in all individuals examined the gene contains 1 or more mutations that disrupt RNA splicing which give rise to a variety of mRNAs in different individuals. In both pig and mouse TDH cDNAs there was no evidence of alternatively splicing . In humans, arginine-214 is replaced by a stop codon. On translation all the human mRNAs would generate a variety of truncated proteins ranging from 157 to 230 residues, some of which would also contain deletions of residues 96–146; whereas the size of the core of TDH enzyme (residues 48–364) differs by only 2 residues in other species, including some bacterial TDH proteins . The human truncated proteins would be non-functional since they would be unable to make appropriate contacts with the substrates, L-threonine and NAD+. They have lost most of the carboxy-terminal domain, which by homology with GALE [26–29], would be expected to bind L-threonine and also have lost various regions of the NAD+ binding motif that extends from exon 1 to exon 6. In comparison, even single point missense mutations in the human GALE gene disrupt protein function resulting in epimerase-deficiency galactosemia .
At present, no known human genetic disease has been associated with defects in the threonine dehydrogenase and 2-amino-3-ketobutyrate coenzyme A ligase biochemical pathway. This may be because the enzymatic activity of L-serine/threonine dehydratase is sufficient to metabolise L-threonine in humans. The mitochondrial threonine dehydrogenase enzyme is thought to act in the maintenance of free somatic threonine concentration derived from dietary threonine  suggesting that humans may not be able to regulate the level of circulating threonine as well as other mammals. In vertebrates, L-threonine is degraded by two major enzymatic pathways and attempts to determine their relative contribution in humans has been by indirect methods. Zhao et al. measured threonine oxidation by the production of labelled CO2 in adult humans from labelled threonine and concluded that the conversion of threonine to glycine through the threonine dehydrogenase pathway was not important if it exists at all . More recently, Darling et al. used a more sensitive method to measure the production of labelled glycine and CO2 and suggested that there was some threonine catabolism via the threonine dehydrogenase pathway, but it accounted for only 7–11% of total . Direct demonstration of the absence of TDH enzymatic activity in human tissues such as liver remains to be demonstrated. In contrast, in normally-fed pigs and rats 80 to 87% of L-threonine catabolism occurs via threonine dehydrogenase [15, 16]. Since the TDH gene is not functioning in humans, what enzyme(s) could be responsible for the small percentage of threonine catabolism to glycine? In bacteria, threonine aldolase also yields glycine, but mammals are thought to lack the "genuine" threonine aldolase . However, serine hydroxymethyltransferase exhibits a low threonine aldolase activity in mammalian liver .
Whether the first dehabilitating mutation was the loss of the splice acceptor site preceding exon 6 or the arginine-214 to stop codon mutation is unknown, nor is it known when in human evolution that a functional TDH gene was lost. However, the arginine codon CGA is used in only 11.1% of arginine residues in humans, being prone to mutate to a stop codon. The TDH gene has been conserved throughout evolution, being found in bacteria and other mammals , so why has it not been conserved in man? How could such a mutation establish its self in the ancestral population? It is likely that the mutation must have conferred some selectable advantage, under the prevailing environmental conditions, on those individuals who carried it, and arose at a time when the ancestral population was small. Under conditions of protein starvation, threonine dietary intake could have been a limiting factor on growth, survival and successful reproduction and a reduction in the rate of threonine catabolism would have conferred a selective advantage on those individuals with defective TDH gene. Additionally, if we consider that the threonine catabolism pathway is also a glycine synthesis pathway, then a reduction in the production of glycine in inhibitory glycinergic neurons  may have contributed to human neural evolution.
Since humans lack a functioning threonine dehydrogenase enzyme and human parasites such as trypanosomes do possess one (Edgar and Horn, unpublished results, GenBank AF529241), the parasite threonine dehydrogenase enzyme is a potential target for therapeutic intervention. Indeed, in trypanosomes such as Trypanosoma brucei, which causes sleeping sickness, L-threonine dehydrogenase is an important metabolic enzyme and inhibition of this enzyme by a wide range of sulphydryl reagents, such as tetraethylthiuram disulphide, leads to a loss of trypanosome viability [38–40].
Loss of other metabolically important genes in man results in disease susceptibility. Man and primates are scurvy-prone, having lost the L-gulono-gamma-lactone oxidase gene that is found in most other eukaryotes, and are unable to synthesize L-ascorbic acid . Man and primates have also lost the urate oxidase enzyme that catalyses the conversion of uric acid to allantoin. This results in a high concentration of uric acid in the blood, predisposing man to hyperuricemia that can lead to gouty arthritis and renal stones . Humans have recently lost 2 functional genes involved in sialic acid function. They are the CMP-N-acetylneuraminic acid hydroxylase gene (CMAH)  and the siglec-like molecule (Siglec-L1) . However, no diseases have yet been associated with the loss of these genes. The CMAH enzyme converts the sialic acid, N-acetylneuraminic acid to N-glycolylneuraminic acid, potentially affecting recognition by a variety of endogenous and exogenous sialic acid-binding lectins. Siglecs are immunoglobulin superfamily member lectins that selectively recognize different sialic acids types and siglec-L1 preferentially recognizes N-glycolylneuraminic acid. To date, no disease has been associated with the loss of the TDH gene, but humans may not be able to metabolise high protein diets as efficiently as other mammals.
The human L-threonine 3-dehydrogenase gene is an expressed pseudogene, which accounts for the very low levels of threonine oxidation measured in humans by the production of labelled CO2 from labelled threonine. This suggests that the L-serine/threonine dehydratase pathway may be the only route in the catabolism of threonine in humans. The presence of a functional TDH gene in key mammal species such as pigs and mice and its loss in man should be taken into consideration when utilising hepatocytes in bioartificial livers and pharmacokinetic studies.
Genotyping of genomic DNA from individuals by restriction enzyme digests and DNA sequencing
Human genomic DNA was isolated from peripheral blood . Regions of genomic DNA surrounding exon 4 and 6 splice acceptor sites were amplified by PCR using primers ATTGCGTGGCTACCAGTGA and CGATCTCCCGAAGATTCTTGT for exon 4 and GAATGAGATTTCAGAAAAAGGCAGG and AACCAGTTGTTCCTCCTCCA for exon 6, using the Advantage 2 cDNA polymerase mix (BD-Clontech, UK). Amplification conditions were: 30 cycles of 94°C for 10 sec and 57°C for 10 sec. PCR products were desalted using the QIAquick PCR purification kit (Qiagen, UK). Amplicons from the exon 4 splice acceptor site were digested in appropriate buffer with the restriction enzyme AciI. Amplicons from the exon 6 splice acceptor site were digested with the restriction enzyme Hsp92II. The amplicons were also sequenced directly using the big dye terminator cycle sequencing ready reaction kit and AmpliTaq DNA polymerase FS and run on an ABI 377 automated DNA sequencers (both from PE Applied Biosystems, UK).
Molecular cloning of human L-threonine dehydrogenase cDNAs
Clones encoding the human L-threonine dehydrogenase cDNA sequence were obtained by touchdown PCR amplification from liver and lung cDNA libraries using primers derived from regions of the sequence of the human genomic DNA clone RP11-110L10 which had homology to the 5' and 3' ends of the ORF of the porcine TDH cDNA sequence. The primers were: ATGCTGTTCATTAGGATGCTGA and GTTGGCTTGGGCAACTCTG and the cycling conditions were 94°C for 10 sec, 64°C for 10 sec and 72°C for 1 min less -1.0°C per cycle for 8 cycles followed by 24 cycles with an annealing temperature of 56°C. PCR products were examined by agarose gel electrophoresis and stained with ethidium bromide. For cloning, PCR products were excised from low-melting point agarose gels and the agarose digested with agarase (Promega, UK). The PCR products were cloned into the T-A vector pCR4-TOPO (Invitrogen, The Netherlands) and sequenced in both directions.
Tissue and cellular distribution of L-threonine dehydrogenase mRNA by RT-PCR
Human cDNA from 14 tissues (BD-Clontech) was analysed for the relative expression of TDH and the housekeeping gene, β-actin. Approximately, 0.2 ng of oligo-dT primed cDNA (derived from poly A+ RNA) from each tissue was amplified by PCR using Taq Gold polymerase (AB Applied Biosystems). For the analysis of TDH expression in 15 cultured cell isolates and cell lines, total RNA was extracted using guanidine thiocyanate and treated with DNase-I to remove any contaminating genomic DNA (total RNA isolation system, Promega). Total RNA was reverse transcribed with random hexamer primers using an AMV RNase H- reverse transcriptase, ThermoScript (Invitrogen). Approximately, cDNA derived from 50 ng of total RNA was used in each PCR. Tissue and cell master mixes were divided into gene specific mixes with the addition of PCR primers to a final concentration of 200 μM. The L-threonine dehydrogenase primers were: exon 7 and 8 boundary, GCCAGGCCATAGCGGAT and exon 8, TGTTTCCACCCCCAGTCCTT and produced a 73 bp amplicon and the β-actin primers were as previously described  and produced a 208 bp amplicon. The amplification conditions were; a 10 min hot start to activate the polymerase followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. The amplicons were examined by ethidium bromide stained agarose gel electrophoresis.
I thank Athina Milona for assistance with the genotyping and the Advanced Biotechnology Centre for DNA sequencing (Charing Cross Campus, Imperial College).
- Strain AJ, Neuberger JM: A bioartificial liver – state of the art. Science 2002, 295:1005–1009.View ArticlePubMedGoogle Scholar
- Tsiaoussis J, Newsome PN, Nelson LJ, Hayes PC, Plevris JN: Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems. Liver Transpl 2001, 7:2–10.View ArticlePubMedGoogle Scholar
- Enard W, Khaitovich P, Klose J, Zollner S, Heissig F, Giavalisco P, Nieselt–Struwe K, Muchmore E, Varki A, Ravid R, et al.: Intra– and interspecific variation in primate gene expression patterns. Science 2002, 296:340–343.View ArticlePubMedGoogle Scholar
- Cross DM, Bayliss MK: A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development. Drug Metab Rev 2000, 32:219–240.View ArticlePubMedGoogle Scholar
- Dabos KJ, Nelson LJ, Bradnock TJ, Parkinson JA, Sadler IH, Hayes PC, Plevris JN: The simulated microgravity environment maintains key metabolic functions and promotes aggregation of primary porcine hepatocytes. Biochim Biophys Acta 2001, 1526:119–130.PubMedGoogle Scholar
- Hoskin SO, Gavet S, Milne E, Lobley GE: Does glutamine act as a substrate for transamination reactions in the liver of fed and fasted sheep? Br J Nutr 2001, 85:591–597.View ArticlePubMedGoogle Scholar
- Leoncini R, Vannoni D, Di Pietro MC, Guerranti R, Rosi F, Pagani R, Marinello E: Restoration of rat liver L–threonine dehydratase activity by pyridoxamine 5'–phosphate: the half–transaminating activity of L–threonine dehydratase and its regulatory role. Biochim Biophys Acta 1998, 1425:411–418.PubMedGoogle Scholar
- FAO/WHO/UNU: Energy and protein requirements. Report of a Joint FAO/WHO/UNU Expert Consultation. World Health Organ Tech Rep Ser 1985, 724:1–206.Google Scholar
- Borgonha S, Regan MM, Oh SH, Condon M, Young VR: Threonine requirement of healthy adults, derived with a 24–h indicator amino acid balance technique. Am J Clin Nutr 2002, 75:698–704.PubMedGoogle Scholar
- Dale RA: Catabolism of threonine in mammals by coupling of L–threonine 3–dehydrogenase with 2–amino–3–oxobutyrate–CoA ligase. Biochim Biophys Acta 1978, 544:496–503.PubMedGoogle Scholar
- Boylan SA, Dekker EE: L–threonine dehydrogenase. Purification and properties of the homogeneous enzyme from Escherichia coli K–12. J Biol Chem 1981, 256:1809–1815.PubMedGoogle Scholar
- Aoyama Y, Motokawa Y: L–Threonine dehydrogenase of chicken liver. Purification, characterization, and physiological significance. J Biol Chem 1981, 256:12367–12373.PubMedGoogle Scholar
- Pagani R, Leoncini R, Righi S, Guerranti R, Lazzeretti L, Marinello E: Mitochondrial L–threonine dehydrogenase. Biochem Soc Trans 1992, 20:379S.PubMedGoogle Scholar
- Tressel T, Thompson R, Zieske LR, Menendez MI, Davis L: Interaction between L–threonine dehydrogenase and aminoacetone synthetase and mechanism of aminoacetone production. J Biol Chem 1986, 261:16428–16437.PubMedGoogle Scholar
- Bird MI, Nunn PB: Metabolic homoeostasis of L–threonine in the normally–fed rat. Importance of liver threonine dehydrogenase activity. Biochem J 1983, 214:687–694.PubMedGoogle Scholar
- Ballevre O, Cadenhead A, Calder AG, Rees WD, Lobley GE, Fuller MF, Garlick PJ: Quantitative partition of threonine oxidation in pigs: effect of dietary threonine. Am J Physiol 1990, 259:E483–491.PubMedGoogle Scholar
- House JD, Hall BN, Brosnan JT: Threonine metabolism in isolated rat hepatocytes. Am J Physiol Endocrinol Metab 2001, 281:E1300–1307.PubMedGoogle Scholar
- Hammer VA, Rogers QR, Freedland RA: Threonine is catabolized by L–threonine 3–dehydrogenase and threonine dehydratase in hepatocytes from domestic cats (Felis domestica). J Nutr 1996, 126:2218–2226.PubMedGoogle Scholar
- Zhao XH, Wen ZM, Meredith CN, Matthews DE, Bier DM, Young VR: Threonine kinetics at graded threonine intakes in young men. Am J Clin Nutr 1986, 43:795–802.PubMedGoogle Scholar
- Darling PB, Dunn M, Sarwar G, Brookes S, Ball RO, Pencharz PB: Threonine kinetics in preterm infants fed their mothers' milk or formula with various ratios of whey to casein. Am J Clin Nutr 1999, 69:105–114.PubMedGoogle Scholar
- Darling PB, Grunow J, Rafii M, Brookes S, Ball RO, Pencharz PB: Threonine dehydrogenase is a minor degradative pathway of threonine catabolism in adult humans. Am J Physiol Endocrinol Metab 2000, 278:E877–884.PubMedGoogle Scholar
- Edgar AJ: Molecular cloning and tissue distribution of mammalian L–threonine 3–dehydrogenases. BMC Biochem 2002, 3:19.View ArticlePubMedGoogle Scholar
- Edgar AJ, Polak JM: Molecular cloning of the human and murine 2–amino–3–ketobutyrate coenzyme A ligase cDNAs. Eur J Biochem 2000, 267:1805–1812.View ArticlePubMedGoogle Scholar
- Kozak M: An analysis of 5'–noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987, 15:8125–8148.View ArticlePubMedGoogle Scholar
- Sobolev V, Sorokine A, Prilusky J, Abola EE, Edelman M: Automated analysis of interatomic contacts in proteins. Bioinformatics 1999, 15:327–332.View ArticlePubMedGoogle Scholar
- Thoden JB, Hegeman AD, Wesenberg G, Chapeau MC, Frey PA, Holden HM: Structural analysis of UDP–sugar binding to UDP–galactose 4–epimerase from Escherichia coli. Biochemistry 1997, 36:6294–6304.View ArticlePubMedGoogle Scholar
- Thoden JB, Holden HM: Dramatic differences in the binding of UDP–galactose and UDP–glucose to UDP–galactose 4–epimerase from Escherichia coli. Biochemistry 1998, 37:11469–11477.View ArticlePubMedGoogle Scholar
- Thoden JB, Wohlers TM, Fridovich–Keil JL, Holden HM: Human UDP–galactose 4–epimerase. Accommodation of UDP–N–acetylglucosamine within the active site. J Biol Chem 2001, 276:15131–15136.View ArticlePubMedGoogle Scholar
- Thoden JB, Henderson JM, Fridovich–Keil JL, Holden HM: Structural analysis of the Y299C mutant of Escherichia coli UDP–galactose 4–epimerase. Teaching an old dog new tricks. J Biol Chem 2002, 277:27528–27534.View ArticlePubMedGoogle Scholar
- Jones DT: Protein secondary structure prediction based on position–specific scoring matrices. J Mol Biol 1999, 292:195–202.View ArticlePubMedGoogle Scholar
- Bauer AJ, Rayment I, Frey PA, Holden HM: The molecular structure of UDP–galactose 4–epimerase from Escherichia coli determined at 2.5 A resolution. Proteins 1992, 12:372–381.View ArticlePubMedGoogle Scholar
- Kelley LA, MacCallum RM, Sternberg MJE: Enhanced Genome Annotation using Structural Profiles in the Program 3D–PSSM. J Mol Biol 2000, 299:499–520.View ArticlePubMedGoogle Scholar
- Thoden JB, Wohlers TM, Fridovich–Keil JL, Holden HM: Crystallographic evidence for Tyr 157 functioning as the active site base in human UDP–galactose 4–epimerase. Biochemistry 2000, 39:5691–5701.View ArticlePubMedGoogle Scholar
- Brenner S, Venkatesh B, Yap WH, Chou CF, Tay A, Ponniah S, Wang Y, Tan YH: Conserved regulation of the lymphocyte–specific expression of lck in the Fugu and mammals. Proc Natl Acad Sci USA 2002, 99:2936–2941.View ArticlePubMedGoogle Scholar
- Wohlers TM, Christacos NC, Harreman MT, Fridovich JL–Keil: Identification and characterization of a mutation, in the human UDP–galactose–4–epimerase gene, associated with generalized epimerase–deficiency galactosemia. Am J Hum Genet 1999, 64:462–470.View ArticlePubMedGoogle Scholar
- Ogawa H, Gomi T, Fujioka M: Serine hydroxymethyltransferase and threonine aldolase: are they identical? Int J Biochem Cell Biol 2000, 32:289–301.View ArticlePubMedGoogle Scholar
- Legendre P: The glycinergic inhibitory synapse. Cell Mol Life Sci 2001, 58:760–793.View ArticlePubMedGoogle Scholar
- Cross GA, Klein RA, Linstead DJ: Utilization of amino acids by Trypanosoma brucei in culture: L–threonine as a precursor for acetate. Parasitology 1975, 71:311–326.View ArticlePubMedGoogle Scholar
- Linstead DJ, Klein RA, Cross GA: Threonine catabolism in Trypanosoma brucei . J Gen Microbiol 1977, 101:243–251.PubMedGoogle Scholar
- Baker JR, Selden LF: Trypanosoma (Schizotrypanum) dionisii as a model for chemotherapeutic studies related to Chagas's disease. Trans R Soc Trop Med Hyg 1981, 75:80–85.View ArticlePubMedGoogle Scholar
- Nishikimi M, Fukuyama R, Minoshima S, Shimizu N, Yagi K: Cloning and chromosomal mapping of the human nonfunctional gene for L–gulono–gamma–lactone oxidase, the enzyme for L–ascorbic acid biosynthesis missing in man. J Biol Chem 1994, 269:13685–13688.PubMedGoogle Scholar
- Wu XW, Lee CC, Muzny DM, Caskey CT: Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA 1989, 86:9412–9416.View ArticlePubMedGoogle Scholar
- Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, Muchmore EA, Nelson DL, Warren ST, Varki A: A mutation in human CMP–sialic acid hydroxylase occurred after the Homo–Pan divergence. Proc Natl Acad Sci USA 1998, 95:11751–11756.View ArticlePubMedGoogle Scholar
- Angata T, Varki NM, Varki A: A second uniquely human mutation affecting sialic acid biology. J Biol Chem 2001, 276:40282–40287.PubMedGoogle Scholar
- John SW, Weitzner G, Rozen R, Scriver CR: A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res 1991, 19:408.View ArticlePubMedGoogle Scholar
- Steuerwald N, Cohen J, Herrera RJ, Brenner CA: Analysis of gene expression in single oocytes and embryos by real–time rapid cycle fluorescence monitored RT–PCR. Mol Hum Reprod 1999, 5:1034–1039.View ArticlePubMedGoogle Scholar